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Oxidative stress (OS) is implicated in the pathophysiology of multiple conditions, including cardiovascular disease 
(CVD).1 Although the harmful cellular effects of free radical 
species in vitro remain undisputed, observational evidence 
along with clinical trials of free radical scavengers has been 
uniformly disappointing.2,3 This has promoted the concept that 
free radicals may not constitute clinically important sources of 
oxidants and that nonfree radical species may be of equal or 
greater importance.4
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Proteins are susceptible to oxidation through alterations of 
reactive aminothiol residues such as cysteine and glutathione. 
These covalent modifications serve to alter the cellular signal-
ing activity of the proteins, thereby coupling redox modifica-
tions of aminothiols to functional activity.5 Importantly, these 
aminothiols can be quantified in plasma to assess the oxidant 
burden in vivo.6 Of these, cysteine constitutes the major ami-
nothiol pool extracellularly that reacts readily with oxidants to 
form its oxidized disulphide cystine. Intracellularly, glutathi-
one is a major antioxidant that helps eliminate peroxides and 
maintain cellular redox, and its oxidized form is glutathione 
disulfide.4 Increased OS, measured as higher levels of cystine, 
lower levels of glutathione, or altered ratios of oxidized to 
reduced aminothiols, is associated with cellular dysfunction, 
aging, risk factors for CVD, and subclinical vascular disease, 
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and are likely to be reliable markers of systemic OS and anti-
oxidant defense.7–13
However, there remains a need to determine whether oxi-
dant burden as indicated by alterations in the levels or ratios of 
these aminothiols is clinically relevant and determines adverse 
outcomes. This would support the use of these aminothiols 
as biomarkers of OS and potentially promote development 
of novel antioxidant therapies. We thus sought to determine 
whether the major aminothiols and their respective ratios 
would be associated with increased mortality and cardiovas-
cular events in a prospectively followed high-risk population.
Methods
Study Population
Study participants aged 20 to 90 years were recruited as part of the 
Emory Cardiovascular Biobank, an ongoing prospective cohort of 
patients enrolled prior to undergoing coronary angiography for inves-
tigation or management of coronary artery disease (CAD) across 
three Emory Healthcare sites with collection of extensive data on 
demographic characteristics, medical history, medication use, behav-
ioral habits, and risk factor prevalence.14,15
Recruited patients were stable at the time of enrollment and 
undergoing an elective procedure, although stable patients with 
non–ST-segment–elevation myocardial infarction (MI), defined using 
international criteria were also included and classified as acute MI.16 
CAD burden was quantified using the semiquantitative Gensini score, 
as previously described.16 Left ventricular function was expressed 
using ejection fraction.17 Finally glomerular filtration rate (GFR) 
was estimated using the Chronic Kidney Disease Epidemiology 
Collaboration (CKD-EPI) formula.18 Subjects were excluded if they 
had a history of heart transplantation, recent transfusion, immuno-
suppressant use, malignancy, or significant infections or any vitamin 
supplements in the previous 6 weeks. Specific dietary intake pat-
terns were not documented but blood samples and measurements 
were taken after an overnight fast before planned coronary angiog-
raphy, except in <1% of patients who underwent angiography emer-
gently on the same day. The study was approved by the Institutional 
Review Board at Emory University, and all subjects provided written 
informed consent.
Follow-Up and Outcomes
The cohort was prospectively followed for determination of the pri-
mary outcome of all-cause death and the secondary outcomes of car-
diovascular death and the composite of death/or nonfatal MI. This 
was performed by personnel blinded to aminothiol data, through tele-
phone interview, chart review, and linkage with the Social Security 
Death Index and state records. Cardiovascular death was defined as 
death attributable to an ischemic cardiovascular cause (fatal MI, isch-
emic stroke, peripheral arterial disease) or sudden death attributable 
to an unknown but presumed cardiovascular cause in high-risk CAD 
patients. Medical records were accessed or requested to validate all 
self-reported events including MI, which was defined using standard 
criteria as above.16 Fifteen patients (1%) were lost to follow-up and 
were excluded from analysis, leaving 1411 patients with complete 
biomarker and follow-up data.
Measurement of Aminothiols and C-Reactive 
Protein
We measured plasma cysteine (CyS), its oxidized form cystine 
(CySS), glutathione (GSH), and its oxidized form glutathione disul-
phide (GSSG) in all subjects using high-performance liquid chroma-
tography mass spectrometry. A full methods and protocol article has 
been published previously outlining sample collection, processing, 
and analysis steps in detail.6 Summary details are also presented in the 
online-only Data Supplement, but briefly, arterial blood samples were 
drawn via syringe immediately after placement of a femoral arterial 
sheath (prior to heparin or saline flush or any coronary intervention) 
and transferred into preprepared Eppendorf tubes containing preser-
vatives to retard auto-oxidation, centrifuged, and stored at −80°C 
for no more than 2 months before transfer to the laboratory. Sample 
collection and storage conditions in this way have been previously 
verified.6 Analyses by high-performance liquid chromatography were 
performed after dansyl derivatization on a 3-aminopropyl column 
with fluorescence detection. Metabolites were identified by coelution 
with standards and quantified by integration relative to the internal 
standard, with validation relative to external standards as previously 
described.6 Ratios of oxidized to reduced aminothiols (cystine/cys-
teine and glutathione disulphide/glutathione) are expressed directly. 
The coefficients of variation for each of the aminothiols were as fol-
lows: cysteine 3.8%, cystine 3.2%, glutathione 5%, and glutathione 
disulphide 9.7%. High-sensitivity C-reactive protein (hsCRP) levels 
were quantified using a sandwich immunoassay (R&D Systems, 
Minneapolis, MN). Minimum detectable hsCRP concentrations were 
0.1 mg/l.
Statistical Methods
Continuous variables are presented as means±SD or as median (inter-
quartile range) and categorical variables as proportions (%) with 
one-way analysis of variance and chi-squared tests used to determine 
differences between groups.
Before analysis, aminothiol measures were non-normally distrib-
uted and were natural log +1 transformed. Furthermore, to make the 
effects comparable between markers, the log-transformed variables 
were standardized to have mean 0 and SD 1. They were assessed as 
continuous and categorical traits, initially by per unit log increase and 
per SD increment and then by a 1×SD cut-off to classify high and low 
values. Survival analysis was performed using Kaplan–Meier curves 
as well as Cox proportional-hazards regression in models adjusted 
first for age, gender, and then additionally for body mass index (kg/
m2), GFR (l/min), presence of diabetes mellitus, hypertension, total 
cholesterol (mg/dL), high-density lipoprotein (mg/dL), current 
smoking, statin use, acute MI at enrollment, left ventricular function 
(ejection fraction; %), Gensini score, and plasma hsCRP at baseline. 
Given that inflammation and oxidative stress are biologically inter-
related, an interaction term between hsCRP and each of the markers 
(including their ratios) was initially included in the model. Interaction 
between age and each marker was also considered to examine any 
potential age-modifying effects. Missing covariate data (range, 0% to 
3%) were imputed and sensitivity analysis with unimputed data found 
results to be similar. The proportional hazards assumption for Cox 
models was evaluated by plots of Schoenfeld residuals and formal 
testing (a χ2 test calculated as the sum of Schoenfeld residuals), with 
no significant violations of the assumption found.
The incremental value of the aminothiol markers for risk predic-
tion was tested before and after their addition to a clinical model with 
traditional risk predictors (age, gender, body mass index, GFR, dia-
betes mellitus, hypertension, total cholesterol, high-density lipopro-
tein, current smoking, statin use, acute MI, left ventricular function, 
Gensini score). The C-statistic and category-free net reclassification 
improvement as well as integrated discrimination improvement that 
can account for censored data were calculated as a measure of risk 
discrimination.19–22 We set the truncation time at 5 years. The result-
ing risk discrimination metrics indicate the performance of the given 
model in predicting events that occurred in the time range from base-
line to 5 years. P values <0.05 from 2-sided tests were considered to 
indicate statistical significance. Statistical analyses were performed 
using SPSS 20.0 (Chicago, IL), SAS (Cary, NC), and R (3.1.0).
Results
Baseline characteristics of the 1411 patients are presented in 
Table 1 and were reflective of a typical population recruited at 
coronary angiography. The mean age of the cohort was 63.2 
(±11.3) years, 66% male, 32% with diabetes mellitus, 69% 
with hypertension or hyperlipidemia, and 16% were current 
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smokers. Approximately 72% had significant CAD (>50% 
luminal stenosis) on angiography, 14% had presented with 
evidence of acute MI (all stable non–ST-segment–elevation 
MI), and 46% were treated with revascularization during the 
admission at which they were enrolled (Table 1).
Relationship Between Aminothiols
The oxidized aminothiol, cystine was almost 8-fold more 
abundant than its reduced form cysteine, whereas the 
reduced aminothiol glutathione was 40 times more abun-
dant than its oxidized form glutathione disulphide (Table 1). 
There were modest correlations between the various ami-
nothiols, whereas hsCRP was only marginally associated 
with the aminothiol markers (Table I in the online-only Data 
Supplement).
Relationship Between Aminothiols and 
Demographic and Clinical Features
In univariate analyses, higher plasma cystine levels (high OS) 
were associated with older age, female gender, higher body 
mass index, impaired renal function (lower GFR), presence of 
diabetes mellitus, hypertension, lower total cholesterol levels, 
statin use, impaired left ventricular function (lower ejection 
fraction), greater CAD burden (Gensini), and greater inflam-
mation (hsCRP). Of these, only age, sex, body mass index, 
GFR, diabetes mellitus, and hypertension were independently 
associated with plasma cystine in a multivariate model. Higher 
glutathione levels (less OS) were associated with younger 
age, lower GFR, absence of diabetes mellitus and hyperten-
sion, lower CAD burden, and higher total cholesterol. Of these 
only age, GFR, CAD burden, and total cholesterol remained 
Table 1. Patient Characteristics
All (N=1411) No Event (n=1164) Event (n=247)
Clinical characteristics
Age, y 63.2 (11.3) 62.0 (11.1) 69.0 (11.0)
Male, % 66.3 66.2 66.8
Caucasian, % 85.7 85.2 88.3
BMI, kg/m2 29.9 (6.41) 30.2 (6.4) 28.5 (6.4)
GFR, ml/min 73.1 (21.6) 75.3 (20.2) 62.5 (24.6)
Hypertension, % 68.9 66.9 78.1
Hyperlipidemia, % 68.4 67.8 71.7
Total cholesterol, mg/dL 172.2 (45.7) 174.4 (45.7) 161.4 (44.1)
LDL, mg/dL 99.6 (38.5) 101.4 (39.2) 91.2 (34.5)
HDL, mg/dL 41.2 (12.3) 41.4 (12.1) 40.3 (13.2)
Diabetes mellitus, % 32.2 29.9 43.3
Current smoking, % 16.4 16.4 16.6
Acute MI, % 14.3 13.2 19.8
LVEF, % 53.7 (11.9) 54.9 (10.8) 48.0 (15.3)
Angiographic CAD
Significant >50%, % 71.5 69.8 81.9
Normal <10%, % 19.1 20.9 8.7
Median Gensini Score (IQR) 14.5 (1–51) 13.0 (0–44) 28 (5–121)
Revascularization at Enrollment, % 46 44.8 52.5
Medication use
Statin use, % 74.4 74.6 73.1
Aspirin use, % 83 83.4 81.4
ACE or ARB use, % 62.7 62.3 64.9
Beta blocker use, % 63.8 62.2 71.5
Inflammation (median, IQR)
C-reactive protein, mg/L 2.9 (1.2–7.1) 2.6 (1.2–6.4) 4.7 (1.75–14.0)
Oxidative stress (median, IQR)
Cystine, μmol/L 97.6 (83.3–115.0) 96.1 (82.3–112.3) 106.9 (90.4–130.6)
Cysteine, μmol/L 12.2 (10.1–14.7) 12.2 (10.1–14.4) 12.3 (9.6–16.1)
Glutathione, μmol/L 1.17 (0.92–1.47) 1.19 (0.94–1.48) 1.07 (0.82–1.43)
Glutathione disulphide, μmol/L 0.02 (0.01–0.03) 0.02 (0.01–0.03) 0.02 (0.02–0.04)
Mean (SD) values, median (IQR) values and % shown unless stated. ACE indicates angiotensin converting 
enzyme; ARB, angiotensin receptor blocker; BMI, body mass index; CAD, coronary artery disease; GFR, 
glomerular filtration rate; HDL, high-density lipoprotein; IQR, interquartile range; LDL, low-density lipoprotein; 
LVEF, left ventricular ejection fraction; and MI, myocardial infarction.
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independently associated with plasma glutathione. Higher 
cysteine levels also correlated independently with GFR, dia-
betes mellitus, CAD burden, and total cholesterol whereas 
glutathione disulfide did not show any associations aside from 
an inverse association with GFR (Table IIA and IIB in the 
online-only Data Supplement).
Relationships Between Individual Aminothiols and 
Outcomes
During a mean follow-up of 4.7 (±2.1) years (median, 5.3; 
interquartile range, 3.1–6.2), representing 6570 person-years 
of follow-up, 247 patients experienced the primary outcome of 
death, of which there were 169 cardiovascular deaths and 314 
composite outcomes of death/MI. Patients who experienced 
the primary outcome were generally older and had more risk 
factors and disease burden as shown in Table 1. Independent 
clinical predictors of outcomes are presented in Table III in the 
online-only Data Supplement.
The baseline cystine (P<0.001) and glutathione (P=0.002) 
levels were both associated with risk of future death after 
adjustment for age and sex (log values, Table 2). These associa-
tions persisted after further adjustment for important covariates 
(see methods) including hsCRP (P=0.001 and P=0.006, respec-
tively). After standardization, to permit marker comparisons, a 
1-SD increment in cystine and a 1-SD decrease in glutathione 
was associated with a 26% and 20% increase in risk of death 
after adjustment for all risk factors, respectively (Table 2).
This association was also evident when cystine and gluta-
thione levels were categorized into quartiles (Kaplan–Meier 
log rank P<0.001 and P=0.002, respectively; Figure I and 
Table IV in the online-only Data Supplement). Examination 
of the Kaplan–Meier plots revealed a possible threshold 
effect, especially for glutathione.
We further explored this by using a 1-SD cut point 
to define high and low levels of aminothiol markers (see 
Methods). Survival analysis confirmed a worse prognosis for 
patients with high cystine (>+1SD; >129.8 μmol/L) and for 
those with low glutathione (<−1SD, <0.68 μmol/L) levels (log 
rank P<0.001 for both; Figure 1). Both a high cystine level 
and low glutathione level were each associated with a 2- to 
3-fold increase in age and sex adjusted risk of death (hazard 
ratio [HR], 2.05; 95% confidence interval [CI],1.53–2.75; HR, 
3.16; 95% CI, 2.20–4.54; respectively). After adjustment for 
all covariates, a high cystine level was associated with a HR of 
1.63 (95% CI, 1.19–2.21) and a low glutathione level of 2.19 
(95% CI, 1.50–3.19).
Importantly, both cystine and glutathione were indepen-
dently associated with the primary outcome of death, when 
entered into the same multivariate model. Furthermore, both 
of these aminothiols were also associated with the secondary 
outcomes of cardiovascular death and the composite of death 
and MI (Table 2). Glutathione in particular showed a greater 
effect size for cardiovascular death compared to all-cause 
death. However, their respective couples, cysteine (reduced) 
and glutathione disulphide (oxidized) were not associated 
with the outcomes examined (data not shown).
Relationship Between Aminothiol Ratios and 
Outcomes
We also examined the ratio of cystine to glutathione, as a 
novel measure of extracellular oxidation to intracellular reduc-
ing capacity and demonstrated a highly significant associa-
tion with the primary outcome (P<0.001; Table 3, Figure 1). 
Patients with a >+1SD level of cystine/glutathione ratio, 
reflecting a high extracellular oxidant burden and low intra-
cellular reducing capacity, demonstrated a HR of 1.92 (95% 
Table 2. Cox Regression Survival Analysis for the Individual Aminothiol Markers Showing Significant Association With Adverse 
Events
Continuous (log) Standardized (per SD) Categorized (High Versus Low)
HR (95% CI) HR (95% CI) HR (95% CI)
Aminothiol Outcome
Age- and 
Sex-Adjusted Fully Adjusted Model
Age- and 
Sex-Adjusted Fully Adjusted Model
Age- and 
Sex-Adjusted Fully Adjusted Model
Cystine (oxidized) Death (n=247) 4.02 (2.38–6.78) 
P<0.001
2.42 (1.40–4.17) 
P=0.001
1.44 (1.25–1.64) 
P<0.001
1.26 (1.09–1.45) 
P=0.001
2.05 (1.53–2.75) 
P<0.001
1.63 (1.19–2.21) 
P=0.002
Death/MI (n=314) 3.15 (1.99–4.99) 
P<0.001
2.06 (1.28–3.32) 
P=0.003
1.35 (1.20–1.52 
P<0.001)
1.21 (1.07–1.37) 
P=0.003
1.88 (1.44–2.46), 
P<0.001
1.54 (1.16–2.04), 
P=0.003
CV Death (n=169) 3.90 (2.07–7.33) 
P<0.001
2.06 (1.07–3.96) 
P=0.031
1.42 (1.21–1.68) 
P<0.001
1.21 (1.02–1.43) 
P=0.031
2.16 (1.52–3.07) 
P<0.001
1.63 (1.12–2.36) 
P=0.010
Glutathione 
(reduced)
Death (n=247) 1.82 (1.42–2.33) 
P<0.001
1.57 (1.22–2.02) 
P=0.001
1.24 (1.08–1.43) 
P=0.002
1.20 (1.05–1.37) 
P=0.006
3.16 (2.20–4.54) 
P<0.001
2.19 (1.50–3.19) 
P<0.001
Death/MI (n=314) 1.73 (1.38–2.17) 
P<0.001
1.51 (1.20–1.90) 
P<0.001
1.23 (1.08–1.39) 
P=0.001
1.20 (1.06–1.34) 
P=0.003
2.66 (1.89–3.74) 
P<0.001
1.89 (1.32–2.70) 
P<0.001
CV Death (n=169) 1.88 (1.40–2.53) 
P<0.001
1.63 (1.20–2.20) 
P=0.002
1.21 (1.03–1.43) 
P=0.023
1.18 (1.01–1.38) 
P=0.041
3.63 (2.39–5.50) 
P<0.001
2.53 (1.63–3.92) 
P<0.001
Cox regression analysis of aminothiol markers as continuous and categorized measures, with risk of adverse outcomes. Cystine categorized as high if >+1 SD and 
low if ≤+1 SD; Glutathione categorized as low if <−1SD and high if ≥−1 SD; Cysteine (reduced) and Glutathione disulphide (oxidized) did not show any significant 
associations (data not shown). Full model includes adjustment for age, sex, body mass index, glomerular filtration rate, diabetes mellitus, hypertension, total cholesterol, 
high-density lipoprotein, current smoking, statin use, acute myocardial infarction, left ventricular ejection fraction, Gensini score, and Ln C-reactive protein. CI indicates 
confidence interval; CV, cardiovascular; HR, hazard ratio; and MI, myocardial infarction.
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CI, 1.39–2.64) for death after full adjustment for all covariates 
(Table 3). Similar significant associations were noted for the 
secondary outcomes of cardiovascular death (HR, 1.91; 95% 
CI, 1.34–2.72) and the composite of death/MI (HR, 1.88; 95% 
CI, 1.40–2.52).
In contrast, although the direct ratios within the extracel-
lular and intracellular compartments of cystine (oxidized) to 
cysteine (reduced) and glutathione disulphide (oxidized) to 
glutathione (reduced) were associated with the studied out-
comes in adjusted models, the associations were attenuated in 
comparison with those for cystine, glutathione, or the cyste-
ine/glutathione ratio (Table 3).
CAD and MI Subgroup Analyses
There was no significant heterogeneity in the association 
between the cystine/glutathione ratio and adverse events 
based on baseline characteristics. Thus, among patients with 
obstructive CAD, those with high cystine/glutathione ratio 
had a HR of 1.80 (95% CI, 1.27–2.54) in comparison with 
3.11 (95% CI, 1.19–8.15) for those with nonobstructive CAD. 
Although there was no significant interaction, the risk of a high 
cystine/glutathione ratio was higher in those with acute MI in 
comparison with those without, HR 3.87 (95% CI, 1.74–8.63) 
and HR 1.82 (95% CI, 1.26–2.62), respectively.
Inflammation and Oxidant Stress
Given that no significant interaction between hsCRP and each 
of the markers (including their ratios) was found (results not 
shown) and both hsCRP and the cystine/glutathione ratio were 
independently associated with risk of death, we devised a sim-
ple multi-marker score, using high/low categories to identify 
the potential value of combining inflammation and OS mea-
sures for predicting future events. A score of 0 (n=647) rep-
resented both low inflammation (low hsCRP, defined as <3 
mg/L [median])23 and low OS (low cystine/glutathione ratio 
[by SD as above]), whereas a score of 2 reflected both high 
hsCRP and high cystine/glutathione (n=84). A score of 1 was 
given to the remaining 661 subjects (Figure 2). In comparison 
with those with a score of 0, those with a score of 1 had a 
covariate adjusted HR of 1.46 (95% CI, 1.08–1.97) for risk 
of death, whereas those with a score of 2 had a HR of 3.26 
(95% CI, 2.17–4.90). Thus, patients with a score of 0, 1, or 2 
experienced a 1-year death rate of 1.1%, 4.9%, or 14.5% or 
a 5-year event rate of 9.7%, 17.3%, and 41.5%, respectively.
Discrimination Testing
When compared with a standard model for risk of death, con-
sisting of traditional risk factors (see Methods), the addition 
of hsCRP, hsCRP + the ratio of cystine/glutathione, and the 
combination of these 2 biomarkers as a multi-marker score 
improved the risk discrimination significantly, including 
C-statistic, net reclassification improvement, and integrated 
discrimination improvement (Table 4). Specifically, whereas 
addition of the individual aminothiols cystine or glutathione 
did not improve risk discrimination, the ratio of cystine/glu-
tathione improved both the net reclassification improvement 
(HR, 0.109; 95% CI, 0.011–0.176) and integrated discrimina-
tion improvement (HR, 0.012; 95% CI, 0.001–0.029; Table 4).
Discussion
Herein we demonstrate that the plasma aminothiols cystine 
and glutathione associate with risk of future death in a high-
risk population with CAD. This effect is independent of, 
and additive to, that of inflammation as assessed by hsCRP. 
Quantification of plasma aminothiol markers may thus repre-
sent an important advance for in vivo assessment of clinically 
important OS.
Specifically, we show that patients with high OS captured 
as (1) a high level of oxidized cystine, representing greater 
extracellular oxidant burden, (2) a low level of reduced gluta-
thione, representing low intracellular reducing capacity, or (3) 
a high ratio of the 2, have a 2-fold increase in risk of mortal-
ity over a mean of 5 years independent of age and other risk 
factors including inflammation. Whereas previous attempts 
at quantifying aminothiol mediated OS have used the redox 
potential of cystine or glutathione disulphide using the Nernst 
equation,6 we found that the directly combined, cross com-
partment ratio of cystine to glutathione is simple and practical 
to calculate and able to discriminate risk, thus representing 
an improved approach to capturing the overall burden of OS 
in vivo.
Control of protein redox state via thiol-disulfide switch-
ing is critical for normal cellular activities and for maintain-
ing physiological and pathophysiological functions including 
Figure 1. Kaplan–Meier curves for association between high vs low levels of cystine, glutathione, and the cystine/glutathione ratio. High 
vs low categorization was defined by SD cut off (see Methods). Log rank P values and number of patients within each category are 
shown.
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promotion of CVD. This includes (1) experimental evidence 
for effects on proinflammatory signaling, mitochondrial oxi-
dation, nuclear factor KB activation, and elevated expression 
of genes for monocyte recruitment to endothelial cells5,7,8,24; 
(2) association with clinical risk factors such as aging, obesity, 
and smoking9,25,26; (3) translational studies confirming asso-
ciation between aminothiols and worse endothelial function, 
carotid intima media thickness, and arterial stiffness11,27,28; 
and (4) prospective outcome data in patients at high CVD risk 
as presented here. In totality, these findings support the use 
of plasma levels of oxidized and reduced aminothiols as key 
biomarkers of OS and cellular health and potentially as new 
therapeutic targets.
The utility of these aminothiols in clinical practice requires 
further testing. Whereas addition of cystine and glutathione 
individually did not improve risk discrimination beyond a 
standard clinical model, addition of the cystine/glutathione 
ratio did improve both risk reclassification metrics. Given the 
interplay between inflammation and OS at a molecular level, 
and with additive effect on risk, we devised and tested a sim-
ple multi-marker score combining the biomarkers of each, for 
ease of clinical use. This simple 3-point score clearly strati-
fied risk and when added to a clinical model also improved 
the C-statistic and metrics of risk reclassification. Thus, a 
combination of biomarkers, in this case reflecting aminothiol-
mediated OS and inflammation-quantified by CRP, may offer 
a valuable approach for clinical risk stratification as has been 
recently described.14
Mechanistically, these findings may have implications for 
understanding other observations. Homocysteine, an impor-
tant aminothiol, is biosynthesized from dietary methionine, 
and in the presence of folate and B vitamins converts to cyste-
ine by cystathione synthase (Figure II in the online-only Data 
Table 3. Cox Regression Survival Analysis for Oxidized to Reduced Ratios of Aminothiol Markers With the Primary Outcome of 
Death
Continuous (log) Standardized (per SD) Categorized (High v Low)
HR (95% CI), P Value HR (95% CI), P Value HR (95% CI), P Value
Aminothiol Ratio Outcome
Age- and 
Sex-Adjusted Fully Adjusted Model
Age- and 
Sex-Adjusted Fully Adjusted Model
Age- and 
Sex-Adjusted Fully Adjusted Model
Cystine/Glutathione 
ratio
Death (n=247) 2.16 (1.65–2.82) 
P<0.001
1.74 (1.34–2.27) 
P<0.001
1.47 (1.29–1.68) 
P<0.001
1.32 (1.16–1.50) 
P<0.001
2.26 (1.65–3.09) 
P<0.001
1.92 (1.39–2.64) 
P<0.001
Death/MI (n=314) 1.97 (1.56–2.49) 
P<0.001
1.65 (1.31–2.08) 
P<0.001
1.40 (1.25–1.58) 
P<0.001
1.29 (1.14–1.44) 
P<0.001
2.17 (1.63–2.90) 
P<0.001
1.88 (1.40–2.52) 
P<0.001
CV Death (n=169) 2.13 (1.59–2.86) 
P<0.001
1.66 (1.21–2.28) 
P=0.002
1.45 (1.24–1.71) 
P<0.001
1.29 (1.10–1.51) 
P=0.002
2.31 (1.58–3.36) 
P<0.001
1.91 (1.34–2.72) 
P<0.001
Cystine/Cysteine 
ratio
Death (n=247) 1.87 (1.28–2.73) 
P<0.001
1.50 (1.05–2.15) 
P=0.027
1.23 (1.09–1.40) 
P=0.001
1.15 (1.02–1.29) 
P=0.027
1.72 (1.24–2.39) 
P=0.001
1.36 (0.97–1.91) 
P=0.07
Death/MI (n=314) 1.78 (1.27–2.51) 
P=0.001
1.50 (1.08–2.08) 
P=0.015
1.21 (1.08–1.36) 
P=0.001
1.14 (1.03–1.28) 
P=0.015
1.57 (1.15–2.12) 
P=0.004
1.31 (0.96–1.80) 
P=0.09
CV Death (n=169) 1.72 (1.09–2.71) 
P=0.021
1.32 (0.86–2.04) 
P=0.20
1.20 (1.03–1.39) 
P=0.021
1.10 (0.95–1.27) 
P=0.20
1.74 (1.12–2.58) 
P=0.006
1.30 (0.87–1.95) 
P=0.21
Glutathione 
disulphide/ 
Glutathione ratio
Death (n=247) 1.34 (1.12–1.60) 
P=0.001
1.21 (1.01–1.46) 
P=0.035
1.22(1.10–1.37) 
P=0.001
1.14 (1.01–1.29) 
P=0.035
1.59 (1.10–2.29) 
P=0.014
1.36 (0.93–1.98) 
P=0.111
Death/MI (n=314) 1.41 (1.20–1.65) 
P<0.001
1.31 (1.12–1.53) 
P=0.001
1.25 (1.13–1.39) 
P<0.001
1.20 (1.08–1.33) 
P=0.001
1.78 (1.29–2.45) 
P<0.001
1.55 (1.11–2.14) 
P=0.009
CV Death (n=169) 1.37(1.07–1.699) 
P=0.004
1.22 (0.98–1.53) 
P=0.07
1.23 (1.07–1.42) 
P=0.004
1.14 (0.99–1.32) 
P=0.074
1.70 (1.10–2.62) 
P=0.017
1.43 (0.92–2.24) 
P=0.11
Cox regression analysis of aminothiol marker ratios as continuous and categorized measures, with risk of adverse outcomes. All ratios categorized as high if >+1 
SD and low if ≤+1 SD. Full model includes adjustment for age, sex, body mass index, glomerular filtration rate, diabetes mellitus, hypertension, total cholesterol, high-
density lipoprotein, current smoking, statin use, acute myocardial infarction, left ventricular ejection fraction, Gensini score, and Ln C-reactive protein. CI indicates 
confidence interval; CV, cardiovascular; HR, hazard ratio; and MI, myocardial infarction.
Figure 2. Covariate adjusted survival analysis for the multi-
marker score by Cox regression, combining low vs high hsCRP 
(inflammation) and low vs high cystine/glutathione ratio (oxidative 
stress [OS]). A score of 0 (blue line, n=647) represents low 
inflammation and low OS, whereas a score of 2 (red line, n=84) 
represents high inflammation and high OS. A score of 1 (green 
line, n=661) represents either high inflammation or high OS only. 
hsCRP indicates high-sensitivity C reactive protein.
Patel et al  Oxidative Stress and Mortality Risk  367
Supplement). While patients with genetic hyperhomocys-
tinemia are prone to severe atherosclerosis, folate supplemen-
tation and homocysteine reduction does not appear to reduce 
CVD risk.29,30 This may be because cysteine is independently 
maintained from homocysteine and represents a more abun-
dant and reactive aminothiol that on oxidation forms cystine, 
which is 30 times more abundant than homocysteine and 
perhaps is a more pathological component. Although some 
studies have shown association between total cysteine and 
CVD,31,32 none until now has examined the individual oxi-
dized and reduced components or their respective contribu-
tion to the oxidant burden. These data may thus offer a partial 
explanation for the failure of homocysteine targeted therapy 
and possible new treatment opportunities.
Although experimental data support the role of free radi-
cal biology in OS, clinical attempts at improving outcomes 
with free radical scavengers (vitamins C, E, etc) have been 
uniformly disappointing.2,33 Our findings support the hypoth-
esis that in vivo, OS may also be driven by nonfree radical 
processes, raising the possibility that alternative antioxidative 
therapies may be more effective. In humans there is no cur-
rently known pathway to reduce cystine to cysteine, although 
cystine levels are in part controlled by the Xc system acting 
as a highly efficient glutamate-cystine transporter.34 Cellular 
expression of this transporter declines with age, potentially 
explaining the association with cystine and age that we and 
others have observed. In contrast zinc enhances expression 
of this system and could represent a therapeutic option to 
reduce plasma cystine and OS. Indeed a recent pilot study in 
patients with macular degeneration has revealed reductions in 
plasma levels of oxidized cystine with zinc supplementation, 
suggesting that levels can be manipulated with therapeutic 
interventions.35
Strengths and Limitations
Strengths of our study include its prospective design, large 
sample size, exploration of both reduced and oxidized ami-
nothiols, long follow-up, use of robust clinical outcomes, and 
exploration of the interaction with inflammation assessed by 
hsCRP. We did not have dietary information on our subjects, 
and ingestion of sulfur-rich amino acids may influence plasma 
aminothiol levels. However, after a meal, cysteine shows rapid 
distribution and cystine levels increase for 2 to 3 hours and 
almost all of our patients were fasting for >8 hours, which 
minimized the likely dietary changes on aminothiol levels. We 
did not have detailed drug information to explore whether thiol 
containing medications impacted on measured levels, and it is 
possible that some patients taking these drugs may have non-
representative levels. Our population is also not representative 
of all populations, and thus our findings may not be generaliz-
able, and require further validation in different groups.
Finally, as an observational study we cannot infer causal-
ity, and confounding by CAD remains possible. Nonetheless, 
oxidative stress is an accepted mechanism for plaque devel-
opment and previous associations with upstream risk factors 
and subclinical phenotypes in those without CAD, as well as 
sensitivity analysis in those with and without CAD showing a 
consistent effect in both groups, suggests reverse causation is 
less likely. However confounding can never be fully excluded 
without interventional studies, but even if causality is not con-
firmed, this does not limit the value of these thiols for use 
as biomarkers of intracellular and extracellular oxidative 
stress, analogous to use of CRP as a biomarker of systemic 
inflammation.
Conclusions and Implications
A high extracellular oxidant burden or reduced intracellular 
antioxidant capacity quantified through assessment of plasma 
aminothiols is associated with higher mortality in patients 
with CAD. As well as representing potentially novel therapeu-
tic targets, OS measured in this way could complement risk 
stratification in conjunction with assessment of inflammation 
assessed by hsCRP. Further studies will evaluate non–high-
performance liquid chromatography methods of aminothiol 
assessments to facilitate their wider use as biomarkers and to 
investigate whether therapies such as zinc supplementation, 
seeking to reduce plasma cystine can alter OS and improve 
outcomes.
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CLINICAL PeRSPeCTIve
Although oxidative stress is a critically important process in atherosclerosis, observational evidence and clinical trials of 
free radical scavengers have proven uniformly disappointing. This has promoted the concept that clinically important oxida-
tive stress may be mediated by nonfree radical species. Proteins with reactive aminothiols are susceptible to oxidation, and 
quantification of these reduced and oxidized (redox) residues offers an alternative means of quantifying in vivo oxidative 
stress and oxidant burden. Having developed means to reliably collect and quantify these markers in plasma, we have previ-
ously shown associations with multiple risk factors for cardiovascular disease as well as with subclinical markers such as 
arterial stiffness and intima media thickness. However, whether these markers are clinically relevant has remained unknown. 
In this study, we now present long-term outcome data demonstrating association between these redox markers and adverse 
cardiovascular outcomes and mortality. These findings are important as they support the use of these aminothiols as novel 
and reliable biomarkers of oxidative stress. Importantly, given that oxidation of these aminothiols leads to altered cellular 
signaling, these findings may offer new opportunities for therapeutic interventions for reducing the adverse clinical impact 
of oxidative stress in vivo.
